Osteonecrosis of the jaw and bisphosphonates - Putting the risk in perspective

New Zealand Medical Journal

Volumn 119, Issue 1246, 2006, Pages

  Bolland, Mark ^a   Hay, David ^b   Grey, Andrew ^a   Reid, Ian ^a   Cundy, Tim ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BONE CANCER; BONE NECROSIS; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; JAW DISEASE; JAW RADIOGRAPHY; MALIGNANT NEOPLASTIC DISEASE; MOUTH EXAMINATION; OSTEOPOROSIS; PAGET BONE DISEASE; PREVALENCE; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT DURATION;

EID: 84860041978     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. American Dental Association. Osteonecrosis of the jaw. URL: http://www.ada.org/prof/resources/topics/osteonecrosis.asp
2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-7.
3. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-34.
4. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567-75.
5. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753-61.
6. Polizzotto MN, Cousins V, Schwarer AP. Bisphosphonate-associated osteonecrosis of the auditory canal. Br J Haematol. 2006;132:114.
7. American Dental Association. Expert Panel Recommendations: Dental Management of Patients on Oral Bisphosphonate Therapy. URL: http://www.ada.org/prof/resources/topics/ topics_osteonecrosis_recommendations.pdf
8. Bone HG, Santora AC. Ten years' experience with alendronate for osteoporosis in postmenopausal women: author reply [Letter]. N Engl J Med. 2004;351:191-2.
9. Hoff AO, Toth BB, Altundag K, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol. 2006;24(suppl):8528.
10. Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Trial. J Bone Miner Res. 2006;21:817-28.
11. Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002;23:508-16.
12. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int. 2005;16:581-9.
13. Walker N, Norton R, Vander Hoorn S, et al. Mortality after hip fracture: regional variations in New Zealand. N Z Med J. 1999;112:269-71.
14. Davidson CW, Merrilees MJ, Wilkinson TJ, et al. Hip fracture mortality and morbidity - can we do better? N Z Med J. 2001;114:329-32.
15. Reid IR, Nicholson GC, Weinstein RS, et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med. 1996;101:341-8.
16. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med. 2005;353:898-908.
17. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev. 2002:CD002068.
18. Djulbegovic B, Wheatley K, Ross J, et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev. 2002:CD003188.
19. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2005:CD003474.
20. Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol. 2005;23:8219-24.
21. Gibbs RD, Hay KD, Ting GS. Our current practice for removal of teeth in patients who are taking oral alendronate (Fosamax). NZ Dental Association News. 2006;130:36-7.